Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis
Tóm tắt
The renal handling of ceftazidime was studied in 8 patients with cystic fibrosis and 10 healthy controls. The renal clearance of ceftazidime (CLRcz) was measured after an intravenous single dose and during low and high plasma concentration steady-state infusions. The glomerular filtration rate (GFR) was simultaneously estimated by inulin clearance (CLinul). The average CLRcz (mean ± SD) was higher in cystic fibrosis patients (125 ± 20 ml/min/1.73m2) than in healthy controls (100 ± 9 ml/min/1.73m2) [p < 0.005]. Also CLinul (mean ± SD) was increased in cystic fibrosis patients (132 ± 30 ml/min/1.73m2) compared with healthy controls (103 ± 8 ml/min/1.73m2) [p < 0.02]. The mean renal clearance ratios of ceftazidime to inulin were close to unity after both the single dose and low and high dose steady-state infusions both in cystic fibrosis patients and in controls. These findings suggest that the glomerular filtration rate is the principal determinant of the elimination rate of ceftazidime. However, in all cystic fibrosis patients with a CLinul exceeding 125 ml/min/1.73m2 the clearance ratio was below unity, indicating tubular reabsorption of ceftazidime occurs in these individuals. The results demonstrate a higher but also more variable GFR in cystic fibrosis patients (74 to 174 ml/min/1.73m2), resulting in increased and accordingly variable ability to eliminate ceftazidime in cystic fibrosis. However, these pharmacokinetic changes are not large enough to call for special dosage considerations for ceftazidime in cystic fibrosis.
Tài liệu tham khảo
Arvidsson A, Alván G, Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatrica Scandinavica 72: 293–294, 1983
Arvidsson A, Borgå O, Alván G. Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption. Clinical Pharmacology and Therapeutics 25: 870–876, 1979
Aurell M, Granerus G. Njurfunktionsprov i vardagssjukvården. Läkartidningen 83: 604–607, 1986
Ayrton J. Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 227–231, 1981
Berg U, Kusoffsky E, Strandvik B. Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatrica Scandinavica 71: 833–838, 1982
De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clinical Pharmacokinetics 13: 228–253, 1987
Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. Journal of Pediatrics 94: 163–164, 1979
Granerus G, Aurell M. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scandinavian Journal of Clinical and Laboratory Investigation 41: 611–616, 1981
Harding SM, Ayrton J, Thornton JE, Munro AJ, Hogg MIJ. Pharmacokinetics of ceftazidime in normal subjects. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 261, 1981a
Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 263–272, 1981b
Hilger HH, Klumper JD, Ullrich KJ. Wasserrückresorption und Jonentransport durch die Sammelsrohrzellen der Säugetierniere. Pflugers Archiv: European Journal of Physiology 267: 218–237, 1958
Hoffstedt B, Haidle S, Walder M. Influence of probenecid on serum and subcutaneous tissue fluid concentrations of benzylpenicillin and ceftazidime in human volunteers. European Journal of Clinical Microbiology 2: 604–606, 1983
Hultqvist C, Borgå O. Enprofylline pharmacokinetics in children with asthma. European Journal of Clinical Pharmacology 32: 533–535, 1987
Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56: 1038–1044, 1975
Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, et al. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 289–295, 1983
Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clinical Pharmacology and Therapeutics 36: 355–362, 1984
Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. Journal of Pediatrics 105: 117–124, 1984
Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, et al. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam and ceftazidime. Antimicrobial Agents and Chemotherapy 20: 567–575, 1981
McPherson MA, Dormer RL. The molecular and biochemical basis of cystic fibrosis. Bioscience Reports 7: 167–185, 1987
Norrby SR. Ceftazidime in clinical practice: a summary. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 405–408, 1983
Rowland M, Tozer TN. (Eds). Clinical pharmacokinetics: concepts and applications, 1st ed., Lea & Febiger Press, Philadelphia, 1980
Rubin MI, Bruck E, Rapoport M. Maturation of renal function in childhood: clearance studies. Journal of Clinical Investigation 28: 1144–1162, 1949
Schachter SH, Spino M, Isles AF, Tesoro A, Prober C, et al. Pharmacokinetics of cefoperazone in patients with cystic fibrosis and healthy volunteers. Proceedings of the 13th International Congress of Chemotherapy, Vienna, August 28–September 2, 1983, pp. 45–48, 1983
Spino M, Chai RP, Isles AF, Balfe JW, Brown RG, et al. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. Journal of Pediatrics 107: 64–70, 1985
Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, et al. Cloxacillin absorption and disposition in cystic fibrosis. Journal of Pediatrics 105: 829–835, 1984
Vogelstein B, Kowarski AA, Lietman PS. The pharmacokinetics of amikacin in children. Journal of Pediatrics 91: 333–339, 1977
Winberg J. The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatrica 48: 443–452, 1959
Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. Journal of Infectious Diseases 35: 828–831, 1977